DOCIVYX Drug Patent Profile

Which patents cover Docivyx, and what generic alternatives are available?

Docivyx is a drug marketed by Avyxa Holdings and is included in one NDA. There is one patent protecting this drug.

This drug has eight patent family members in five countries.

The generic ingredient in DOCIVYX is docetaxel. There are forty-one drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the docetaxel profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Docivyx

A generic version of DOCIVYX was approved as docetaxel by HOSPIRA INC on March 8^th, 2011.

Summary for DOCIVYX

International Patents:	8
US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DOCIVYX

DOCIVYX is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avyxa Holdings	DOCIVYX	docetaxel	SOLUTION;INTRAVENOUS	215813-001	Nov 22, 2022		RX	Yes	Yes			Y
Avyxa Holdings	DOCIVYX	docetaxel	SOLUTION;INTRAVENOUS	215813-002	Nov 22, 2022		RX	Yes	Yes			Y
Avyxa Holdings	DOCIVYX	docetaxel	SOLUTION;INTRAVENOUS	215813-003	Nov 22, 2022		RX	Yes	Yes			Y

International Patents for DOCIVYX

See the table below for patents covering DOCIVYX around the world.

Country	Patent Number	Title	Estimated Expiration
China	111714449
Japan	2018512395
World Intellectual Property Organization (WIPO)	2016149162
China	111728941
China	111728940
China	107427486
European Patent Office	3270912

Supplementary Protection Certificates for DOCIVYX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1667986	28/2013	Austria		PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
0253738	C960002	Netherlands		PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127

DOCIVYX Market Analysis and Financial Projection

Last updated: April 23, 2026

DOCIVYX (Drug) — Investment Scenario and Fundamentals Analysis

DOCIVYX is a brand name that cannot be mapped to a single, verifiable pharmaceutical product, active ingredient, regulatory status, or patent estate using the information provided in this request. Without that mapping, no complete and accurate investment fundamentals or patent-driven risk assessment can be produced.

What is DOCIVYX (active ingredient, dosage form, indication)?

No determinable answer from the request.

What is the commercial and regulatory status needed for an investment thesis?

No determinable answer from the request.

What is the patent and exclusivity landscape to underwrite durable cash flows?

No determinable answer from the request.

What is the investment scenario under patent expiry, exclusivity cliffs, and competitive entry?

No determinable answer from the request.

---

Key Takeaways

• DOCIVYX cannot be evaluated as an investable drug asset without a verified product-to-active-ingredient mapping.
• A patent and exclusivity fundamentals analysis requires the exact active ingredient, indication(s), and jurisdictions tied to DOCIVYX.
• No defensible investment scenario (launch timing, peak sales path, exclusivity cliff, or generic/biosimilar risk) can be constructed from the request as given.

---

FAQs

1. Can you provide a patent landscape for DOCIVYX without the active ingredient?
   No, because patent families are tied to the specific invention and API, not the brand name alone.

2. Does “DOCIVYX” uniquely identify a single drug product globally?
   Not based on the request; brand names can map to different products across markets.

3. Can you model an exclusivity cliff from a brand name only?
   No; exclusivity terms require jurisdiction and the underlying regulatory reference (application type, approval date, and product-specific exclusivity eligibility).

4. Can you assess payer and launch fundamentals without indication details?
   No; budgets, formulary access, and competitive dynamics are indication- and patient-pathway-specific.

5. Is a qualitative outlook enough for investment decisions?
   No; investment underwriting needs specific, verifiable dates, rights, and competitors.

---

References

No sources cited.